The prognostic implications of histologic classification and bromodeoxyuridine labeling index of mixed gliomas.
To clarify the biological and clinical behavior and prognosis of mixed gliomas, 47 patients underwent intraoperative bromodeoxyuridine (BrdU) labeling studies. The mean age was 27.8 years at symptom onset and 31.8 years at labeling (median, 36 years). Forty-five tumors were supratentorial, 30 were frontal, and two were cerebellar; 16 were recurrent at labeling. The median labeling index (LI) was 1% (range, < 1 to 15.1%). Forty-six tumors has oligodendroglial and astrocytic elements, and one had astrocytic and ependymal elements. The median LI was 4.4% in recurrent tumors and < 1% in primary tumors. A higher BrdU LI correlated with an increased risk of recurrence and a shorter time to recurrence. During a median follow-up of 16 months, four patients died; each had a BrdU LI > or = 4.4%. The median time to recurrence was 4.5 months for tumors with BrdU LI's > 5% but was not reached for tumors with LI's < 5% (p < 0.003). The histologic grade of the oligodendroglial component correlated with the median time to recurrence (8 months for Smith Grade C tumors, not reached for Smith Grade B tumors; p < 0.05); there were too few cases to evaluate the median times to recurrence of Smith Grade A and Grade D tumors. The median time to recurrence was not reached for any astrocytic grade, and there were no significant differences in the Kaplan-Meier survival curves. These findings suggest that the BrdU LI and the grade of the oligodendroglial component of mixed gliomas have prognostic significance.
Brain Tumor Research Center, School of Medicine, University of California, San Francisco 94143.
M R
MR
Wacker
T
T
Hoshino
D K
DK
Ahn
R L
RL
Davis
M D
MD
Prados
D000293:Adolescent; D000328:Adult; D001253:Astrocytes / Q000473:pathology; D001932:Brain Neoplasms / Q000401:mortality / Q000473:pathology*; D001973:Bromodeoxyuridine; D002648:Child; D002675:Child, Preschool; D005260:Female; D005910:Glioma / Q000401:mortality / Q000473:pathology*; D006801:Humans; D007150:Immunohistochemistry; D007223:Infant; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009836:Oligodendroglia / Q000473:pathology; D011379:Prognosis; D016019:Survival Analysis
D001973:Bromodeoxyuridine